{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/shingles/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"56b89dcf-d466-50f3-a8a0-3a9477ef3362","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field 57e1ba51-be86-46fc-9df5-4825c0ad4f29 --><h2>How should I diagnose shingles?</h2><!-- end field 57e1ba51-be86-46fc-9df5-4825c0ad4f29 -->","summary":"","htmlStringContent":"<!-- begin item c6b12c2f-b499-46b6-b72c-be8330dfc476 --><!-- begin field 5f8d92dc-9e0c-4f66-9dc9-2cc701e43b13 --><ul><li><strong>Take a history. </strong><ul><li>Ask about the symptoms experienced, including when they started and the location, duration, and severity.</li><li>Identify <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/risk-factors/\">risk factors</a> for shingles, such as immunocompromise due to long-term corticosteroid use.</li></ul></li><li><strong>Examine the person to:</strong><ul><li>Assess for the clinical features of shingles.</li><li>Exclude <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/diagnosis/differential-diagnosis/\">differential diagnoses</a>, such as herpes simplex virus infection and contact dermatitis. </li></ul></li><li><strong>Diagnose shingles on the basis of typical clinical features.</strong><ul><li>There is usually a prodromal phase with abnormal skin sensations and pain in the affected dermatome (area of skin served by an individual nerve). The pain can be described as burning, stabbing, or throbbing; can be intermittent or constant, and may be so severe it interferes with sleep and quality of life. Headache, photophobia, malaise, and fever (less common) may also occur as part of the prodromal phase.</li><li>Within 2–3 days (more rarely up to 7 days), a rash typically appears in a dermatomal distribution. It starts as maculopapular lesions then develops into clusters of vesicles, with new vesicles continuing to form over 3–5 days. The rash is usually painful, itchy, and/or tingly, and, unlike other rashes, does<em> </em>not cross the midline of the body.  </li><li>The vesicles then burst, releasing varicella-zoster virus, and crust over within 7–10 days. </li><li>Healing occurs over 2–4 weeks, and often results in scarring and permanent pigmentation in the affected area.  </li><li><strong>The location of symptoms depends on the affected nerve:</strong><ul><li>In immunocompetent people, the infection usually occurs on the thorax, with dermatomes T1 to L2 most commonly affected.</li><li>In immunocompromised people, symptoms can be more widespread and affect multiple dermatomes (<a class=\"topic-reference internal-reference\" href=\"/topics/shingles/background-information/complications/\">disseminated disease</a>).</li></ul></li><li><strong>Note that:</strong><ul><li>The rash may be atypical in certain groups of people, for example older people (in whom the rash may not be vesicular) and immunocompromised people (in whom the rash may be severe or long-lasting). </li><li>In rare cases, pain without a rash (zoster sine herpete) can occur.</li></ul></li></ul></li><li><strong>Investigations are not usually required in primary care. </strong>If there is diagnostic uncertainty, refer or seek specialist advice.</li></ul><!-- end field 5f8d92dc-9e0c-4f66-9dc9-2cc701e43b13 --><!-- end item c6b12c2f-b499-46b6-b72c-be8330dfc476 -->","topic":{"id":"012e484d-8c14-5168-bb5d-e5acb7d4571a","topicId":"2969a8ac-cb7f-4569-be79-822e6009081a","topicName":"Shingles","slug":"shingles","lastRevised":"Last revised in October 2020","chapters":[{"id":"eeb1b918-6c05-5340-b348-ce2809516623","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ad8b1b2-36bb-5262-ab5a-05763d6e4c7d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b1aed669-8481-5315-ab58-4bb18606e360","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8fef2c66-91dc-57c6-8cd3-4e4eff8d7727","slug":"changes","fullItemName":"Changes"},{"id":"ea603e45-ec07-5201-a182-ebef4c48ef6b","slug":"update","fullItemName":"Update"}]},{"id":"81feec28-1a5d-5a24-9c52-bee13821b03b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb672f83-c2bd-5dd7-9934-78f09729db48","slug":"goals","fullItemName":"Goals"},{"id":"2036bd3f-37bc-5cea-887d-55c3fc68c7cf","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc04b460-a0d8-5e8d-b8d0-c044947b4bd6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ee3573cb-38d5-5d4c-9c9d-cd274242d964","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"52999d3b-9cce-59c5-b588-1f7ad7de33e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"40a91fd6-3c01-5713-85ad-0a5c4379eab9","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"04a0af22-814d-5b14-b28c-7916f1772a4d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"097dfec6-754a-54a8-9d96-44e1c5704248","slug":"definition","fullItemName":"Definition"},{"id":"f20034b1-ae3e-505b-ac16-3e11f2a6653e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e92f0243-b1ac-50d9-a31a-a07a4c61c5a7","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b6f8c581-b332-5d26-ba45-ccfb7189a387","slug":"complications","fullItemName":"Complications"},{"id":"012c8f32-e9cf-5897-a695-4c21cd28ae5d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"81f3feff-d640-5ee2-83fa-af1a4e8b586a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"56b89dcf-d466-50f3-a8a0-3a9477ef3362","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"01bc96b7-ea05-59b9-963a-16b2722b9367","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"acd9aec2-87d6-5084-bd3a-5c0b1d164ab4","fullItemName":"Management","slug":"management","subChapters":[{"id":"9872f447-6f59-502d-b6cb-a0fae6d2c085","slug":"management","fullItemName":"Scenario: Management"},{"id":"9ecdcc36-4fec-5b60-aa42-2032f2c406a4","slug":"prevention","fullItemName":"Scenario: Prevention"}]},{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4445c1da-4f7a-5f12-a909-0112bbd72453","slug":"antiviral-drugs","fullItemName":"Antiviral drugs"},{"id":"1223613b-f5a6-5da6-a311-275f5d6181b2","slug":"zostavax","fullItemName":"Zostavax"}]},{"id":"67979756-a00f-5f10-a93e-81509b35e1a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"625749c2-4e09-57ba-bdee-cd206d8b02d5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"377ce207-6229-5548-aef7-a637f176a94e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19ac0831-d4e2-52c3-b127-e78b1f26fb6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d46d7aff-a113-50d5-afa1-3310aad844d7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d23205e9-41c9-5c70-a9f9-5ce3cfae633a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cf98894b-c083-59fd-8150-f390845960f1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52b727c-ba28-5973-9e3c-e4882a883593","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"81f3feff-d640-5ee2-83fa-af1a4e8b586a","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"636ec7e3-dc63-56fb-b04c-89daf6f1dc5d","slug":"basis-for-recommendation-288","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field ada32faa-db68-410e-9f86-41c122f2ef30 --><h3>Basis for recommendation</h3><!-- end field ada32faa-db68-410e-9f86-41c122f2ef30 -->","summary":null,"htmlStringContent":"<!-- begin item 2884cfd1-a57a-4878-9e79-5437b6350d3f --><!-- begin field c954dab2-b9c0-494a-a371-e963bb9169dc --><p>These recommendations are based on the chapter on <em>Shingles (herpes zoster)</em> in <em>Immunisation against infectious disease</em> (the 'Green book'), published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2016</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Herpes zoster (syn. shingles)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>], the <em>European consensus‐based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017a</a>], the Centers for Disease Control and Prevention (CDC) guideline <em>Shingles (Herpes Zoster) </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>], and on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Schmader, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</p><ul><li>The clinical features of shingles are usually distinctive enough to make an accurate clinical diagnosis once the rash has appeared [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>].</li><li>Important differences between shingles and differential diagnoses include the prodrome, the dermatomal distribution, the vesicle groupings, and pain in the area of the rash [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>]. <ul><li>Shingles usually occurs on the thorax (53% of cases) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>], with dermatomes T1 to L2 most commonly affected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>]. Other dermatomal distributions include cervical (20%), the ophthalmic (first) division of the trigeminal nerve (10–20%), and lumbosacral (11%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Ting, 2019</a>].</li><li>The rash of shingles does not cross the midline, whereas other rashes can [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</li><li>Mucous membranes within the affected dermatome are also involved. Bilateral involvement is rare [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PCDS, 2017</a>].</li></ul></li><li>Investigations are typically not needed but may be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>]:<ul><li>In people with recurring lesions that are suspicious for herpes simplex.</li><li>In people with suspected zoster sine herpete, in which the virus causes pain without lesions.</li><li>For atypical presentations, such as the widely disseminated lesions that may occur in immunocompromised people.</li><li>For differentiating herpes zoster from other vesicular dermatoses, such as contact dermatitis. </li></ul></li><li>Investigations which may be used to diagnose shingles include polymerase chain reaction testing of vesicle or other body fluids to identify varicella-zoster virus DNA, immunohistochemical analysis of skin scrapings, or virus culture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Saguil, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">CDC, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Le, 2019</a>].</li></ul><!-- end field c954dab2-b9c0-494a-a371-e963bb9169dc --><!-- end item 2884cfd1-a57a-4878-9e79-5437b6350d3f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}